Nerivio is a novel wireless neuromodulation wearable from Theranica for drug-free acute treatment of migraine. The device features an electronic housing moulded in a Thermolast M custom-coloured medical-grade thermoplastic elastomer compound from Kraiburg TPE. The device has passed clinical testing, is FDA-authorised and conforms to all applicable IEC/EN 60601 standards for medical devices, and nerve stimulators. The TPE material provides ISO 10993 certified biocompatibility and is supplied in line with new VDI 2017 guidelines.
Non-pharmacological treatment of migraine and other pain conditions has become a challenge, not just in remote areas without ready access to outpatient care facilities, but also under the constraints of social distancing amid the current COVID-19 pandemic. The company Theranica based in Netanya, Israel, has developed an innovative neuromodulation device – Nerivio – addressing both issues with a convenient wearable solution for personalised, app-controlled acute treatment of migraine. The electroceutical device is worn on the arm and uses electronic pulses for inducing a drug-free pain inhibition mechanism. The user-friendly app is available for both Android and iOS smartphones and includes a migraine diary that can be shared with healthcare professionals, for better managing this disabling disease.
In close cooperation with AiT Chemicals, a local supplier of polymers and Kraiburg TPE’s distributor in Israel, Theranica selected a Thermolast M medical-grade TPE that offered the ultimate property profile for this device. It delivers a smooth and velvety surface ‘as moulded’, with durable abrasion resistance to the securing armband and strap of the device. It is biocompatible and offers irritation-free characteristics while meeting cytotoxicity requirements, which have been certified respectively to ISO 10993-10 and ISO 10993-5 standards. The compound is pre-coloured ex works to match the stylish grey surface texture of the armband according to customer requirements.
Following comprehensive clinical clearance, the Nerivio device received a De Novo approval from the U.S. Food and Drug Administration (FDA) for clinical use in May 2019. The FDA classified the wearable as a trunk and limb electrical stimulator to treat headache. It conforms to all applicable IEC/EN 60601 standards for the safety and electromagnetic compatibility of medical electrical equipment, nerve, and muscle stimulators. TIME Magazine acknowledged Nerivio in its appreciation of “100 Best Inventions” in 2019. The device was selected as one of ten winners in the Health Care category based on key factors including originality, creativity, influence, ambition, and effectiveness.
In the United States, Nerivio is already available as a prescribed wearable, including through telemedicine platforms UpScript and Cove. It is expected to be launched in Europe and other regions in 2021.